Drug search by name

Alemtuzumab and Cytopenias

Result of checking the interaction of drug Alemtuzumab and disease Cytopenias for safety when used together.

Check result:

Alemtuzumab <> Cytopenias

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Severe, including fatal, autoimmune anemia and thrombocytopenia, and prolonged myelosuppression have been reported in patients receiving alemtuzumab. It is recommended to withhold therapy for severe cytopenias and to discontinue therapy for autoimmune cytopenias or recurrent/persistent severe cytopenias (except lymphopenia). It is recommended to monitor complete blood counts (CBC) at weekly intervals during therapy and more frequently if worsening anemia, neutropenia, or thrombocytopenia occurs and to assess CD4+ counts after treatment until recovery to >= 200 cells/µL.

Alemtuzumab

Generic Name: alemtuzumab

Brand Name: Campath, Lemtrada

Synonyms: n.a.

What is Alemtuzumab?